INGENIA THERAPEUTICS
Ingenia Therapeutics provider of undisclosed products and services based in Cambridge, Massachusets.
INGENIA THERAPEUTICS
Founded:
2018-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Total Employee:
1+
Status:
Active
Contact:
(781) 491-9005
Total Funding:
4.71 M USD
Similar Organizations
858 Therapeutics
858 Therapeutics is a stealth company specializing in the area of healthcare services, pharmaceutical, and biotechnology.
Gage Cannabis
Gage Cannabis is a craft cannabis brand and operator.
LivWell Enlightened Health
LivWell Enlightened Health is a medical cannabis company producing and retailing multi-state cannabis.
Current Employees Featured
Founder
More informations about "Ingenia Therapeutics"
Ingenia Therapeutics - Crunchbase Company Profile & Funding
Ingenia Therapeutics is a biotechnology company developing a therapeutic antibody candidate to treat multiple diseases, including cancer and inflammatory diseases. It specializes in …See details»
INGENIA Therapeutics
INGENIA Therapeutics is a research-driven biotechnology company. We are committed to the discovery and development of advanced therapeutics for patients afflicted by inflamed and …See details»
INGENIA Therapeutics Company Profile 2024: Valuation, Funding ...
INGENIA Therapeutics General Information Description. Developer of a therapeutic antibody candidate designed for capillary diseases. The company specializes in discovering and …See details»
INGENIA Therapeutics
Sangyeul Han founded INGENIA Therapeutics in 2018. Previously, he worked at Cell Signaling Technology where he led its Antibody Technology and Molecular Biology groups. Before CST, …See details»
Ingenia Therapeutics Inc. - Drug pipelines, Patents, Clinical trials ...
Last update 01 Nov 2024. Ingenia Therapeutics Inc. Startups |See details»
Ingenia Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... Nov 30, 2022: Venture Round …See details»
Ingenia Therapeutics - Company Profile - Tracxn
Dec 5, 2024 Ingenia Therapeutics has filed a notice of an exempt offering of securities to raise $25,000,000.00 in New Equity Investment.intelligence360 • Jul 04, 2024 • Ingenia …See details»
INGENIA Therapeutics - LinkedIn
INGENIA Therapeutics | 826 followers on LinkedIn. INGENIA Therapeutics strives to develop antibodies to treat multiple diseases including cancer & inflammatory diseases | INGENIA …See details»
Ingenia Therapeutics Inc. Company Profile - Dun & Bradstreet
Ingenia Therapeutics Inc. Company Profile | Watertown, MA | Competitors, Financials & Contacts - Dun & BradstreetSee details»
Nona Biosciences and INGENIA Therapeutics Enter into …
Oct 13, 2023 About INGENIA Therapeutics INGENIA is a privately held biotechnology company specializing in a proprietary microvasculature protection technology aimed at offering a means …See details»
IGT-512 - Drug Targets, Indications, Patents - Synapse
IGT-512, Initially developed by Ingenia Therapeutics Inc., Now, its global highest R&D status is Discovery, Therapeutic Areas: Neoplasms, Active Indication: Neoplasms, Active Org.: Ingenia …See details»
Nona Biosciences and INGENIA Therapeutics Enter into …
Oct 13, 2023 Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and INGENIA Therapeutics, a preclinical-stage biotech …See details»
Technology - INGENIA Therapeutics
By modifying endothelial cell signaling, INGENIA technology provides breakthrough vascular therapeutics. Based on our deep understanding of endothelial biology, we found a unique way …See details»
Nona Biosciences and INGENIA Therapeutics Enter into …
CAMBRIDGE, Mass., Oct. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and INGENIA …See details»
IGT-302 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 IGT-302, Initially developed by Ingenia Therapeutics Inc., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Eye Diseases, Active Indication: Glaucoma, …See details»
News - INGENIA Therapeutics
INGENIA Therapeutics & Nona Biosciences Enter into Collaboration Agreement. Oct 19,2023 INGENIA. INGENIA Therapeutics & Mosaic Biosciences present preclinical data. May 02,2022 …See details»
Ingenia Therapeutics | Watertown MA - Facebook
Ingenia Therapeutics, Watertown, Massachusetts. 4 likes. Dedicated to developing breakthrough therapeutics for capillary diseases of high unmet need Ingenia Therapeutics | Watertown MASee details»
IGT-427 - Drug Targets, Indications, Patents - Synapse - Patsnap
Dec 27, 2024 Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.See details»
Inflammatory diseases(Ingenia) - Drug Targets, Indications, Patents ...
Now, its global highest R&D status is Preclinical, Therapeutic Areas: Other Diseases, Active Indication: Inflammation, Active Org.: Ingenia Therapeutics Inc.. Biomedical products DataSee details»